Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.90
0.00 (0.00%)
At close: Nov 17, 2026, 4:00 PM EST
13.89
-0.01 (-0.07%)
After-hours: Nov 17, 2026, 4:12 PM EST

Organon & Co. Revenue

Organon & Co. had revenue of $1.57B in the quarter ending September 30, 2026, a decrease of -1.75%. This brings the company's total for the last twelve months to $6.10B, down -3.21% year-over-year. In the year 2025, Organon & Co. had annual revenue of $6.22B, down -2.92%. That makes Organon & Co. the 2,283rd largest company in the world by revenue and 668th in the United States.

Revenue (ttm)
$6.10B
Revenue Growth
-3.21%
P/S Ratio
0.60
Revenue / Employee
$609,900
Employees
10,000
Market Cap
3.65B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Established Brands 3.69B 59.4%
  • Women's Health 1.75B 28.2%
  • Biosimilars 691.00M 11.1%
  • Other Product Group 82.00M 1.3%

By Geography

Chart
  • Europe and Canada 1.62B 26.0%
  • United States 1.60B 25.8%
  • Latin America, Middle East, Russia and Africa 1.07B 17.2%
  • Asia Pacific and Japan 1.00B 16.1%
  • China 829.00M 13.3%
  • Other International 93.00M 1.5%
Fiscal year ended Dec 31, 2025 See the full Organon & Co. breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20256.22B-187.00M-2.92%
Dec 31, 20246.40B140.00M2.24%
Dec 31, 20236.26B89.00M1.44%
Dec 31, 20226.17B-130.00M-2.06%
Dec 31, 20216.30B-228.00M-3.49%
Dec 31, 20206.53B-1.25B-16.01%
Dec 31, 20197.78B-2.00B-20.46%
Dec 31, 20189.78B-723.00M-6.89%
Dec 31, 201710.50B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Pfizer63.62B
AstraZeneca62.38B
Sanofi57.89B
Novo Nordisk50.70B
Bristol-Myers Squibb Company50.03B
GSK plc44.53B
Amgen38.90B
Gilead Sciences30.99B
Revenue Rankings